NO20043483L - Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus - Google Patents

Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus

Info

Publication number
NO20043483L
NO20043483L NO20043483A NO20043483A NO20043483L NO 20043483 L NO20043483 L NO 20043483L NO 20043483 A NO20043483 A NO 20043483A NO 20043483 A NO20043483 A NO 20043483A NO 20043483 L NO20043483 L NO 20043483L
Authority
NO
Norway
Prior art keywords
melagatran
drug
manufacture
treatment
type
Prior art date
Application number
NO20043483A
Other languages
English (en)
Norwegian (no)
Inventor
Olle Korsgren
Bo Nilsson
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20043483L publication Critical patent/NO20043483L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043483A 2002-01-23 2004-08-20 Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus NO20043483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
NO20043483L true NO20043483L (no) 2004-08-20

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043483A NO20043483L (no) 2002-01-23 2004-08-20 Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus

Country Status (14)

Country Link
US (2) US7045502B2 (de)
EP (1) EP1469874A1 (de)
JP (1) JP2005516035A (de)
KR (1) KR20040075096A (de)
CN (1) CN100430089C (de)
BR (1) BR0306798A (de)
CA (1) CA2472241A1 (de)
IL (1) IL162853A0 (de)
MX (1) MXPA04007192A (de)
NO (1) NO20043483L (de)
NZ (1) NZ533749A (de)
SE (1) SE0200198D0 (de)
WO (1) WO2003061682A1 (de)
ZA (1) ZA200405342B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
NZ700332A (en) 2010-03-30 2017-06-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
PL2968297T3 (pl) 2013-03-15 2019-04-30 Verseon Corp Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej
BR112015023214A8 (pt) 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
RU2017112739A (ru) 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
SG10201907699YA (en) 2015-02-27 2019-09-27 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
BR112021000515A2 (pt) 2018-07-13 2021-04-06 Verseon International Corporation Composto, pró-fármaco do composto, composição farmacêutica, método para tratar e/ou prevenir uma doença ou distúrbio num indivíduo, comprimido, e, processo de fabricação de um comprimido.
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CA2472241A1 (en) 2003-07-31
CN100430089C (zh) 2008-11-05
US7045502B2 (en) 2006-05-16
WO2003061682A1 (en) 2003-07-31
US20050090424A1 (en) 2005-04-28
US20060148720A1 (en) 2006-07-06
KR20040075096A (ko) 2004-08-26
NZ533749A (en) 2006-02-24
JP2005516035A (ja) 2005-06-02
EP1469874A1 (de) 2004-10-27
MXPA04007192A (es) 2004-10-29
CN1729010A (zh) 2006-02-01
BR0306798A (pt) 2004-12-07
SE0200198D0 (sv) 2002-01-23
ZA200405342B (en) 2005-09-28
IL162853A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
EP1510207A4 (de) Therapeutisches arzneimittel gegen diabetes
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL166058A0 (en) Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof
PL372865A1 (en) Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
NO20020764L (no) Benzosyrederivater for behandling av diabetes mellitus
FI20010683A (fi) Menetelmä aineenvaihdunnallisten häiriöiden, erityisesti diabeteksen tai diabetekseen liittyvän sairauden tai tilan hoitamiseksi
NO20043000L (no) Et preparat for behandling av nevrocerebrovaskulaere sykdommer
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003243708A1 (en) Use of bases for the manufacture of a medicament in the treatment of different forms of inflammatory dermatosis
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003223780A1 (en) Treatment for pompe disease
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
NO20025883L (no) Tiazolidinonsalt for behandling av diabetes mellitus
HK1077216A1 (en) Use of thiazole derivatives for the manufacture ofa medicament for the treatment of chronic obstruc tive pulmonary disease
AU2003294952A8 (en) 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same
AU2002307327A1 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application